| Ivabradine in combination with beta-blocker improves symptoms and quality of life in patients with stable angina pectoris: results from the ADDITIONS study. | |
| | |
MedLine Citation:
|
PMID: 22231643 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
AIM: Several clinical trials have demonstrated the antianginal and anti-ischemic efficacy of ivabradine in combination with beta-blocker in patients with stable angina pectoris. The ADDITIONS (PrActical Daily efficacy anD safety of Procoralan(®) In combinaTION with betablockerS) study evaluated the efficacy, safety, and tolerability of ivabradine added to beta-blocker, and its effect on angina symptoms and quality of life in routine clinical practice. METHODS: This non-interventional, multicenter, prospective study included 2,330 patients with stable angina pectoris treated with a flexible dose of ivabradine twice daily in addition to beta-blocker for 4 months. The parameters recorded included heart rate, number of angina attacks, nitrate consumption, tolerance, and quality of life. RESULTS: After 4 months ivabradine (mean dose 12.37 ± 2.95 mg/day) reduced heart rate by 19.4 ± 11.4 to 65.6 ± 8.2 bpm (p < 0.0001). The number of angina attacks was reduced by 1.4 ± 1.9 per week (p < 0.0001), and nitrate consumption by 1.9 ± 2.9 U per week (p < 0.0001). At baseline (i.e., on beta-blocker), half of the patients (51%) were classified as Canadian Cardiovascular Society (CCS) grade II; 29% were CCS grade I. After 4 months' treatment with ivabradine, most of the patients were CCS grade I (68%). The EQ-5D index improved by 0.17 ± 0.23 (p < 0.0001). The overall efficacy of ivabradine was considered by the physicians as "very good" (61%) or "good" (36%) in most patients. Suspected adverse drug reactions were documented in 14 patients; none were severe. CONCLUSION: In daily clinical practice, combining ivabradine with beta-blocker not only reduces heart rate, number of angina attacks, and nitrate consumption, but also improves the quality of life in patients with stable angina pectoris. |
| | |
Authors:
|
Karl Werdan; Henning Ebelt; Sebastian Nuding; Florian Höpfner; Guido Hack; Ursula Müller-Werdan |
Related Documents
:
|
17065033 - Limitations of a simplification antiretroviral strategy for hiv-infected patients with ... 19648823 - Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in... 9128303 - Normalization of esophageal ph with high-dose proton pump inhibitor therapy does not re... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-1-10 |
Journal Detail:
|
Title: Clinical research in cardiology : official journal of the German Cardiac Society Volume: - ISSN: 1861-0692 ISO Abbreviation: - Publication Date: 2012 Jan |
Date Detail:
|
Created Date: 2012-1-10 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101264123 Medline TA: Clin Res Cardiol Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Department of Medicine III, University Hospital Halle (Saale) of the Martin-Luther-University Halle-Wittenberg, Ernst-Grube-Straße 40, 06097, Halle (Saale), Germany, karl.werdan@medizin.uni-halle.de. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Dual-objective STORM reveals three-dimensional filament organization in the actin cytoskeleton.
Next Document: Dual- versus single-coil implantable defibrillator leads: review of the literature.